Table 1.
Baseline Characteristics
| Total (N=39) | |
|---|---|
| Age | |
| Median | 60.0 |
| Range | (28.0–73.0) |
| Gender: Male | 25 (64.1%) |
| ECOG Performance Score | |
| 0 | 27 (69.2%) |
| 1 | 12 (30.8%) |
| Months from initial myeloma therapy to registration | |
| Median | 4.9 |
| Range | (2.6–11.1) |
| Days from first dose of lenalidomide to registration | |
| Median | 141.0 |
| Range | (78.0–311.0) |
| Days from last dose of lenalidomide to registration | |
| Median | 24.0 |
| Range | (14–110.0) |
| Ending lenalidomide Dose | |
| 10 mg | 1 (2.6%) |
| 15 mg | 7 (18.4%) |
| 25 mg | 30 (78.9%) |
| Total number of cycles of lenalidomide | |
| Median | 4.0 |
| Range | (3.0–11.0) |
| Other drugs used in combination with lenalidomide | 39 (100.0%) |
| Dexamethasone | 39 |
| Cyclophosphamide | 1 |
| Velcade | 10 |
| Other | 2 |